Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
27.8M
-
Number of holders
-
160
-
Total 13F shares, excl. options
-
19.5M
-
Shares change
-
+842K
-
Total reported value, excl. options
-
$1.39B
-
Value change
-
+$57.8M
-
Put/Call ratio
-
0.43
-
Number of buys
-
80
-
Number of sells
-
-86
-
Price
-
$71.18
Significant Holders of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) as of Q1 2022
197 filings reported holding ENTA - ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share as of Q1 2022.
ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) has 160 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 19.5M shares
of 27.8M outstanding shares and own 70.4% of the company stock.
Largest 10 shareholders include BlackRock Inc. (3.52M shares), VANGUARD GROUP INC (1.59M shares), FARALLON CAPITAL MANAGEMENT LLC (1.55M shares), STATE STREET CORP (1.31M shares), ARMISTICE CAPITAL, LLC (1.12M shares), RA CAPITAL MANAGEMENT, L.P. (964K shares), NORTHERN TRUST CORP (928K shares), FIRST MANHATTAN CO (789K shares), RENAISSANCE TECHNOLOGIES LLC (607K shares), and DIMENSIONAL FUND ADVISORS LP (594K shares).
This table shows the top 160 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.